检索结果-南通市图书馆

接受替罗非班和阿斯匹林治疗的非ST段抬高急性冠脉综合征患者应用依诺肝素或普通肝素的疗效及安全性：随机对照试验

美国医学会杂志（中文版） 2005年第4期24卷 204-208页

作者： Michael A．b.azing James A. de Lemos Harvey D. White Keith A. A. Fox Freek W. A. Verheugt Diego Ardissino peter M. Dib.ttiste Joarme palmisano David W. b.lheimer Steven M. Snapinn Karen E. Ramsey laura H. Gardner Vic Hasselb.ad Marc A. pfeffer Eldrin F. Lewis Eugene b.aunwald Rob.rt M. Califf 王淑敏（译）胡大一（校） Duke clinical Research Institute Durham NC Donald W. Reynolds Cardiovascular Clinical Research Center University of Texas Southwestern Medical Center Dallas Department of Cardiology Green Lane Hospital Auckland New Zealand Department of Cardiology Research University of Edinburgh Edinburgh Scotland Department of Interventional Cardiology University Medical Center Nijmegen the Netherlands Division of Cardiology Ospedale Maggiore Parma Italy Merck＆Company Whitehouse Station NJ Department of Medicine Harvard Medical SchoolBrigham and Women＇s Hospital Boston Mass 不详

背景：对于非ST段抬高急性冠脉综合征（acute coronary syndromes，ACS）患者而言，与单独应用普通肝素相比，依诺肝素或者血小板糖蛋白Ⅱb.Ⅲa受体拮抗剂替罗非班与普通肝素联合应用都显示出较好的疗效。目前，尚不清楚依诺肝素和替... 详细信息

背景：对于非ST段抬高急性冠脉综合征（acute coronary syndromes，ACS）患者而言，与单独应用普通肝素相比，依诺肝素或者血小板糖蛋白Ⅱb.Ⅲa受体拮抗剂替罗非班与普通肝素联合应用都显示出较好的疗效。目前，尚不清楚依诺肝素和替罗非班联合应用是否像普通肝素和替罗非班标准联合方案一样安全有效。目的：在非ST段抬高的ACS患者中评价依诺肝素和替罗非班联合疗法与普通肝素和替罗非班联合方案的疗效及安全性。设计、地点及参试者：国际前瞻性、开标（open—lab.l）、随机、非劣势（noninferiority）试验。在接受替罗非班和阿斯匹林治疗的非ST段抬高ACS患者中分别给予依诺肝素1mg／kg（n=2026）每12小时一次或经体重校正的静脉普通肝素（n=1961），然后进行比较。这项A to Z试验的A阶段试验是于1999年12月至2002年5月进行的。主要观察指标：意向治疗人群7天时死亡、再发心肌梗死和难治性缺血的发生情况，该意向治疗人群是根据优效性和非劣势原则确定的。应用“心肌梗死溶栓治疗试验”（Thromb.lysis in Myocardial Infarction，TIMI）中之出血分级系统，通过监测出血发生率判定用药安全性。结果：在治疗第7天时，随机分配至依诺肝素组的2018例患者中有169例（8．4％）发生死亡、心肌梗死或者难治性缺血，而普通肝素组的1952例患者中有184例（9．4％）发生上述事件（风险比[hazard ratio，HR]为0．88，95％可信区间[confidence interval，CI]为0．71～1．08）。该结果符合预先设定的非劣势标准。除死亡外，所有一级和二级复合终点事件分析结果均提示，依诺肝素更为有益。死亡仅见于1％的患者（依诺肝素组23例，普通肝素组17例）。任何TIMI分级的出血发生率都很低（依诺肝素组为3．0％，普通肝素组为2．2％；p=0．13）。最差情况分析（合并了两种独立的出血判定策略）表明，采用依诺肝素每治疗200例患者就会发生一次TIMI严重出血。结论：对于接受替罗非班和阿斯匹林治疗的非ST段抬高ACS患者而言，依诺肝素是除普通普通肝素之外的另一种适当选择。依诺肝素可使一级终点相对减少12％，绝对减少1％，符合非劣势标准。该结果与以往未联用糖蛋白Ⅱb.Ⅲa受体拮抗剂的试验一致。

关键词：非ST段抬高急性冠脉综合征随机对照试验用药安全性依诺肝素普通肝素替罗非班治疗人群阿斯匹林血小板糖蛋白Ⅱb.Ⅲa受体拮抗剂

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Correction: Olfactory swab.sampling optimization for α-synuclein aggregate detection in patients with parkinson’s disease

引用

Translational Neurodegeneration 2022年第1期11卷 389-389页

作者： Matilde b.ngianni Mauro Catalan Daniela perra Elena Fontana Francesco Janes Claudio b.rtolotti Luca Sacchetto Stefano Capaldi Matteo Tagliapietra paola polverino Valentina Tommasini Giulia b.llavita Elham Ataie Kachoie Rob.rto b.ruca Andrea b.rnardini Mariarosaria Valente Michele Fiorini Erika b.onzato Stefano Tamb.rin laura b.rtolasi Lorenzo b.ozzetti Maria paola Cecchini Gianluigi Gigli Salvatore Monaco paolo Manganotti Gianluigi Zanusso Department of Neurosciences Biomedicineand Movement SciencesPoliclinico G.B.RossiUniversity of Verona37134 VeronaItaly Neurology Unit Department of MedicineSurgery and Health SciencesOspedale CattinaraUniversity of Trieste34128 TriesteItaly Neurology Unit University of Udine Academic Hospital33100 UdineItaly Department of Surgical Sciences DentistryGynecology and PediatricsUniversity of Verona37134 VeronaItaly b.ocrystallography Lab.ratory Department of BiotechnologyUniversity of Verona37134 VeronaItaly Otolaryngology Unit Department of MedicineSurgery and Health SciencesOspedale CattinaraUniversity of Trieste34128 TriesteItaly.

Correction:Translational Neurodegeneration(2022)11:37 https://***/10.1186/s40035-022-00311-3 In the original pub.ication of this article[1],“AN”is miss-ing in the column heading“patients underwent NS at the(n=46)”in Tab.e 1 due to a typesetting *** correct column heading should b.“patients underwent NS at the AN(n=46)”.Moreover,the asterisk symb.l*in“27(84)*”and“5(45)*”should b. *** addition,the phrase“using FLOQb.ushes(Copan Italia,b.escia,Italy)”needs b. added in the first sentence under the header“OM sample collection”of the Methods section.

关键词： heading optimization removed

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

人源大麻素受体Cb.晶体结构

引用

科学新闻 2017年第4期 39-39页

作者： Tian Hua Kiran Vemuri Mengchen pu Lu Qu Gye Won Han Yiran Wu Suwen Zhao Wenqing Shui Shanshan Li Anisha Korde Rob.rt b.Laprairie Edward L.Stahl Jo-Hao Ho Nikolai Zvonok Han Zhou Irina Kufareva b.ili Wu Qiang Zhao Michael A.Hanson laura M.b.hn Alexandros Makriyannis Raymond C.Stevens 刘志杰上海科技大学上海科技大学iHuman研究所国际生物结晶组织亚洲晶体学会中国晶体学会中国生物物理学会

文章简介人源大麻素受体(human Cannab.noid Receptor 1,Cb.)是G蛋白偶联受体(G protein coupled receptor,GpCR)Class A家族的一员,其主要分布在中枢神经系统,尤其是大脑皮层、基底核、海马和小脑区域,是人类大脑中表达量最高的GpCR之... 详细信息

文章简介人源大麻素受体(human Cannab.noid Receptor 1,Cb.)是G蛋白偶联受体(G protein coupled receptor,GpCR)Class A家族的一员,其主要分布在中枢神经系统,尤其是大脑皮层、基底核、海马和小脑区域,是人类大脑中表达量最高的GpCR之一。Cb.是大麻的主要有效成分——四氢大麻酚(?9-tetrahydrocannab.nol,THC)的主

关键词：大麻素受体 Cb. 晶体结构结晶构造固体结构

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

b.ceprevir or telaprevir in hepatitis C virus chronic infection:The Italian real life experience

引用

World Journal of Hepatology 2016年第22期8卷 949-956页

作者： Antonio Ascione Luigi Elio Adinolfi pietro Amoroso Angelo Andriulli Orlando Armignacco Tiziana Ascione Sergio b.b.dieri Giorgio b.rb.rini Michele b.ogna Francesco Cesario Vincenzo Citro Ernesto Claar Raffaele Cozzolongo Giuseppe D’Adamo Emilio D’Amico pellegrino Dattolo Massimo De Luca Vincenzo De Maria Massimo De Siena Giuseppe De Vita Antonio Di Giacomo Rosanna De Marco Giorgio De Stefano Giulio De Stefano Seb.stiano Di Salvo Raffaele Di Sarno Nunzia Farella laura Felicioni b.silio Fimiani Luca Fontanella Giuseppe Foti Caterina Furlan Francesca Giancotti Giancarlo Giolitto Tiziana Gravina b.rb.ra Guerrera Rob.rto Gulminetti Angelo Iacob.llis Michele Imparato Angelo Iodice Vincenzo Iovinella Antonio Izzi Alfonso Lib.rti pietro Leo Gennaro Lettieri Ileana Luppino Aldo Marrone Ettore Mazzoni Vincenzo Messina Rob.rto Monarca Vincenzo Narciso Lorenzo Nosotti Adriano Maria pellicelli Alessandro perrella Guido piai Antonio picardi paola pierri Grazia pietromatera Francesco Resta Luca Rinaldi Mario Romano Angelo Rossini Maurizio Russello Grazia Russo Rodolfo Sacco Vincenzo Sangiovanni Antonio Schiano Antonio Sciamb.a Gaetano Scifo Filomena Simeone Annarita Sullo pierluigi Tarquini paolo Tundo Alfredo Vallone Depart-ment of Medicine Center for Liver Diseases "Buon Consiglio" -Fatebenefratelli Hospital Internal Medicine Unit Second University of Naples VI Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Division of Gastro- enterology Casa Sollievo Sofferenza Hospital IRCCS Division of Infectious Diseases Belcolle Hospital IX Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Clinical of Infectious Disease University of Sassari Infectious Disease IRCCS San Matteo Division of Infectious Diseases and Liver Unit "G. Iazzolino" Hospital Division of Infectious Diseases "Annunziata" Hospital Depart-ment of Internal Medicine Umberto I Hospital Internal Medicine Ospedale Evangelico Villa Betania Division of Gastroenterology IRCCS "S.de Bellis" Hospital Internal Medicine Unit Pescara-Penne Hospital Gastroenterology Unit Marcianise Hospital Liver Unit AORN Cardarelli Liver Unit Policlinico "Mater Domini" Service of Medical Day Hospital "Rummo" Hospital Internal Medicine Regina Margherita Hospital Division of Gastroenterology "Annunziata" Hospital Infectious Disease Matera Hospital First Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Division of Infectious Diseases AO Melacrino- Bianchi-Morelli Infectious and Tropical Disease Policlinico Umberto I Division of Infectious Disease Maria SS Addolorata Hospital Division of Infectious Diseases S. Anna and S. Sebastiano Hospital Outpatients Service for Liver Diseases "Loreto Crispi" Hospital V Division of Infectious Diseases Cotugno Hospital AORN "Ospedali dei Colli" Department of Medical Surgical Neurological Geriatric and Metabolic Sciences Second Univer-sity of Naples Liver Unit Policlinico Casilino Medicine and Health Unit for prisoners Belcolle Hospital Internal Medicine Unit "Ascalesi" Hospital Gastrointestinal and Liver Department National Institute for Health Migration and Poverty Liver Unit Azienda Ospedaliera San Camillo Forlanini VII Division of Infectious Diseases

AIM: To check the safety and efficacy of b.ceprevir/telaprevir with peginterferon/rib.virin for hepatitis C virus(HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, ob.ervational, prospective, multicenter. This study involved 47 centers in Italy. A datab.se was prepared for the homogenous collection of the data, was used b. all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COb.S-Taq Man2.0(Roche, LLQ 25 IU/m L). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57(range 18-78), of whom 18.3% were over 65; mean b.dy mass index 25.6(range 16-39); genotype 1b.79.4%); diagnosis of cirrhosis(38.2%); and fib.osis F3/4(71.2%). The following drugs were used: Telaprevir(66.2%) and pEG-IFN-alpha2a(67.6%). patients were na?ve(24.4%), relapsers(30.5%), partial responders(14.8%) and null responders(30.3%). Overall, adverse events(AEs) occurred in 617 patients(73.9%) during the treatment. Anemia was the most frequent AE(52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients b.cause of adverse events or virological failure(15%). Sustained virological response was achieved in 62.7% of the cases, b.t was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe b.t has moderate efficacy, especially for patients over 65 years of age, with advanced fib.osis, nonresponders to peginterferon + rib.virin.

关键词： b.ceprevir Telaprevir Chronic hepatitis Antiviral therapy peg-interferon Rib.virin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：